Darapladib

Cat. No.: OB0225WX-2096

Appearance: Solid

Purity: ≥99%

Identity: Confirmed by NMR, and LC-MS.

Size:

INQUIRY Datasheet MSDS

Add to basket

Product Overview

Description: Darapladib is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2) featuring an IC50 value of 0.25 nM.

Synonym: SB-480848; 356057-34-6; Darapladib (SB-480848); SB 480848; N-(2-(Diethylamino)ethyl)-2-(2-((4-fluorobenzyl)thio)-4-oxo-4,5,6,7-tetrahydro-1H-cyclopenta[d]pyrimidin-1-yl)-N-((4'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)methyl)acetamide; N-[2-(Diethylamino)ethyl]-2-[[(4-fluorophenyl)methyl]thio]-4,5,6,7-tetrahydro-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-1H-cyclopentapyrimidine-1-acetamide; 1H-Cyclopentapyrimidine-1-acetamide, N-(2-(diethylamino)ethyl)-2-(((4-fluorophenyl)methyl)thio)-4,5,6,7-tetrahydro-4-oxo-N-((4'-(trifluoromethyl)(1,1'-biphenyl)-4-yl)methyl)-; MFCD18251452; N-[2-(Diethylamino)ethyl]-2-[2-[(4-fluorophenyl)methylsulfanyl]-4-oxo-6,7-dihydro-5h-cyclopenta[d]pyrimidin-1-yl]-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide; N-(2-(Diethylamino)ethyl)-2-(2-((4-fluorobenzyl)sulfanyl)-4-oxo-4,5,6,7-tetrahydro-1H-cyclopentapyrimidin-1-yl)-N-((4'-(trifluoromethyl)biphenyl-4-yl)methyl)acetamide; 4'-(trifluoromethyl)biphenyl-4-yl]methyl}acetamide; N-(2-(Diethylamino)ethyl)-2-(2-(4-fluorobenzylthio)-4-oxo-4,5,6,7-tetrahydro-1H-cyclopenta[d]pyrimidin-1-yl)-N-((4'-(trifluoromethyl)biphenyl-4-yl)methyl)acetamide; N-(2-Diethylamino-ethyl)-2-[2-(4-fluoro-benzylsulfanyl)-4-oxo-4,5,6,7-tetrahydro-cyclopentapyrimidin-1-yl]-N-(4''-trifluoromethyl-biphenyl-4-ylmethyl)-acetamide

CAS No.: 356057-34-6

Compound CID: 9939609

Formula: C₃₆H₃₈F₄N₄O₂S

Formula Weight: 666.77

Specification

Targets&IC50: Lp-PLA2: 0.25 nM

Relative Density: 1.259 g/cm³

Stability: 3 years in powder form.

Storage: Storage at -20°C.

Applications: Darapladib is employed in cardiovascular and clinical research as a selective inhibitor of Lp-PLA2 to investigate the stabilization of atherosclerotic plaques and the reduction of vascular wall inflammation.